Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

BioVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CARSON CITY, NEV., SEPT. 26, 2025 (GLOBE NEWSWIRE) -- BIOVIE INC. (NASDAQ: BIVI) (BIOVIE OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING INNOVATIVE DRUG THERAPIES FOR NEUROLOGICAL AND NEURODEGENERATIVE DISEASES, WILL HOST AN INVESTOR WEBINAR AT 4:15 P.M. ET ON WEDNESDAY, OCT. 8, 2025.

BIOVIE TO HOST LIVE INVESTOR WEBINAR AND Q&A ON OCT. 8

ADDRESS-LC TRIAL IS NOW ENROLLING PATIENTS WITH LONG COVID-RELATED FATIGUE AND COGNITIVE IMPAIRMENT AT SITES ACROSS THE U.S. ADDRESS-LC TRIAL IS NOW ENROLLING PATIENTS WITH LONG COVID-RELATED FATIGUE AND COGNITIVE IMPAIRMENT AT SITES ACROSS THE U.S.

BIOVIE HIGHLIGHTED ADDRESS-LC PHASE 2 TRIAL DESIGN EXPLORING BEZISTERIM FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS OF LONG COVID AT KEYSTONE SYMPOSIA ON LONG COVID AND OTHER POST-ACUTE INFECTION SYNDROMES

CARSON CITY, NEV., AUG. 07, 2025 (GLOBE NEWSWIRE) -- BIOVIE INC. (NASDAQ: BIVI, BIVIW), (BIOVIE OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING INNOVATIVE DRUG THERAPIES TO TREAT CHRONIC DEBILITATING CONDITIONS INCLUDING LIVER DISEASE AND NEUROLOGICAL AND NEURO-DEGENERATIVE DISORDERS, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 6,000,000 UNITS, WITH EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT (THE WARRANTS) (OR PRE-FUNDED UNITS IN LIEU THEREOF, WITH EACH PRE-FUNDED UNIT CONSISTING OF ONE PRE-FUNDED WARRANT (THE PRE-FUNDED WARRANTS) AND ONE WARRANT). EACH UNIT IS BEING SOLD TO THE PUBLIC AT A PRICE OF $2.00 PER UNIT (AND EACH PRE-FUNDED UNIT IS BEING SOLD TO THE PUBLIC AT THE PUBLIC OFFERING PRICE OF EACH UNIT LESS THE $0.0001 PER SHARE NOMINAL EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT). THE GROSS PROCEEDS TO THE COMPANY FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY $12 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES. THE WARRANTS INCLUDED IN THE UNITS AND PRE-FUNDED UNITS HAVE BEEN APPROVED FOR LISTING ON THE NASDAQ CAPITAL MARKET AND ARE EXPECTED TO COMMENCE TRADING UNDER THE SYMBOL BIVIW ON AUGUST 8, 2025. EACH WARRANT WILL BE IMMEDIATELY EXERCISABLE, WILL ENTITLE THE HOLDER TO PURCHASE ONE SHARE OF COMMON STOCK AT AN EXERCISE PRICE OF $2.50 PER SHARE AND WILL EXPIRE FIVE YEARS FROM THE DATE OF ISSUANCE. EACH PRE-FUNDED WARRANT WILL BE IMMEDIATELY EXERCISABLE, WILL ENTITLE THE HOLDER TO PURCHASE ONE SHARE OF COMMON STOCK AND MAY BE EXERCISED AT ANY TIME UNTIL EXERCISED IN FULL. THE COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND WARRANTS CAN ONLY BE PURCHASED TOGETHER IN THE OFFERING BUT WILL BE ISSUED SEPARATELY. THE COMPANY HAS GRANTED THE UNDERWRITER A 45-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 900,000 SHARES OF COMMON STOCK AND/OR PRE-FUNDED WARRANTS AND/OR WARRANTS, OR ANY COMBINATION THEREOF, SOLELY TO COVER OVER-ALLOTMENTS, IF ANY, AT

BIOVIE INC. ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING

BEZISTERIM TREATMENT APPEARS TO BE ASSOCIATED WITH CHANGES IN DNA METHYLATION OF OVER 100 GENES RELATED TO AGING AND DISEASES OF AGING BEZISTERIM TREATMENT APPEARS TO BE ASSOCIATED WITH CHANGES IN DNA METHYLATION OF OVER 100 GENES RELATED TO AGING AND DISEASES OF AGING

BIOVIE PRESENTED DATA HIGHLIGHTING THAT PATIENTS TREATED WITH BEZISTERIM POTENTIALLY EXPERIENCED AN AGE DECELERATION ADVANTAGE COMPARED TO PLACEBO ON 10 DIFFERENT BIOLOGICAL CLOCKS AT THE 2ND WORLD CONFERENCE ON AGING AND GERONTOLOGY

SEASONED LEADERS BRING DEEP EXPERTISE IN NEUROSCIENCE DRUG DEVELOPMENT, STRATEGIC GROWTH, AND CORPORATE FINANCE TO SUPPORT BIOVIE'S MISSION SEASONED LEADERS BRING DEEP EXPERTISE IN NEUROSCIENCE DRUG DEVELOPMENT, STRATEGIC GROWTH, AND CORPORATE FINANCE TO SUPPORT BIOVIE'S MISSION

BIOVIE APPOINTS INDUSTRY VETERANS AMY CHAPPELL, MD, FAAN, AND KAMEEL FARAG TO BOARD OF DIRECTORS

HYBRID, DECENTRALIZED TRIAL OF BEZISTERIM IN EARLY PARKINSON'S DISEASE PRIORITIZES PATIENT ACCESS AND PARTICIPATION HYBRID, DECENTRALIZED TRIAL OF BEZISTERIM IN EARLY PARKINSON'S DISEASE PRIORITIZES PATIENT ACCESS AND PARTICIPATION

BIOVIE HIGHLIGHTS PATIENT-CENTRIC DESIGN OF SUNRISE-PD TRIAL AT ADVANCED THERAPEUTICS IN MOVEMENT & RELATED DISORDERS CONGRESS (ATMRD)

CARSON CITY, NEV., JUNE 24, 2025 (GLOBE NEWSWIRE) -- BIOVIE INC., (NASDAQ: BIVI) (BIOVIE OR THE COMPANY) A CLINICAL-STAGE COMPANY DEVELOPING INNOVATIVE DRUG THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND ADVANCED LIVER DISEASE,TODAY ANNOUNCED THAT A POSTER HIGHLIGHTING THE DECENTRALIZED DESIGN AND PATIENT EXPERIENCE OF ITS PHASE 2 SUNRISE-PD CLINICAL TRIAL EVALUATING BEZISTERIM (NE3107) IN EARLY PARKINSON'S DISEASE WILL BE PRESENTED IN POSTER SESSION AT THE UPCOMING ADVANCED THERAPEUTICS IN MOVEMENT & RELATED DISORDERS CONGRESS , TO BE HELD AT NATIONAL HARBOR, MD, FROM JUNE 27 TO JUNE 30, 2025.

BIOVIE TO PRESENT OVERVIEW OF PHASE 2 SUNRISE-PD TRIAL AT THE ADVANCED THERAPEUTICS IN MOVEMENT & RELATED DISORDERS CONGRESS

CARSON CITY, NEV., MAY 14, 2025 (GLOBE NEWSWIRE) -- BIOVIE INC. (NASDAQ: BIVI), (BIOVIE OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING INNOVATIVE DRUG THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND ADVANCED LIVER DISEASE, TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL KEY OPINION LEADER (KOL) EVENT FEATURING SUZANNE DE LA MONTE, MD, MPH (BROWN UNIVERSITY WARREN ALPERT MEDICAL SCHOOL, PROVIDENCE VA MEDICAL CENTER) AND MARK STACY, MD (MEDICAL UNIVERSITY OF SOUTH CAROLINA COLLEGE OF MEDICINE), WHO WILL JOIN COMPANY MANAGEMENT TO DISCUSS THE UNMET NEED AND CURRENT TREATMENT LANDSCAPE FOR PARKINSON'S DISEASE ON WEDNESDAY, MAY 28, 2025 AT 12:00 PM ET. TO REGISTER, CLICK HERE.

BIOVIE TO HOST VIRTUAL KOL EVENT TO DISCUSS THE PHASE 2 STUDY OF BEZISTERIM FOR THE TREATMENT OF PARKINSON'S DISEASE ON MAY 28, 2025

CARSON CITY, NEV., MARCH 27, 2025 (GLOBE NEWSWIRE) -- BIOVIE INC. (NASDAQ: BIVI), (BIOVIE OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING INNOVATIVE DRUG THERAPIES FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND ADVANCED LIVER DISEASE, TODAY ANNOUNCED THAT IT WILL HOST A VIRTUAL INVESTOR EVENT FEATURING KEY OPINION LEADER (KOL) LINDSAY MCALPINE, MD, BSC (YALE UNIVERSITY), WHO WILL JOIN COMPANY MANAGEMENT TO DISCUSS THE UNMET NEED AND CURRENT TREATMENT LANDSCAPE FOR LONG COVID ON THURSDAY, APRIL 10, 2025 AT 10:00 AM ET. TO REGISTER, CLICK HERE .

BIOVIE TO HOST KOL INVESTOR WEBCAST TO DISCUSS THE LONG COVID TREATMENT LANDSCAPE AND ITS ADDRESS-LC TRIAL ON APRIL 10, 2025

CARSON CITY, NEV., OCT. 28, 2024 (GLOBE NEWSWIRE) -- BIOVIE INC. (NASDAQ: BIVI), (BIOVIE OR THE COMPANY), A CLINICAL-STAGE COMPANY DEVELOPING INNOVATIVE DRUG THERAPIES TO TREAT CHRONIC DEBILITATING CONDITIONS INCLUDING LIVER DISEASE AND NEUROLOGICAL AND NEURO-DEGENERATIVE DISORDERS, TODAY ANNOUNCED THE PRICING OF A REGISTERED DIRECT OFFERING OF 1,146,000 SHARES OF ITS COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES AT A PRICE OF $2.83 PER SHARE, RESULTING IN TOTAL GROSS PROCEEDS OF APPROXIMATELY $3.2 MILLION, BEFORE DEDUCTING THE PLACEMENT AGENT'S FEES AND OFFERING EXPENSES.

BioVie Inc.

BIVI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BioVie Inc.

BIVI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BIVI